QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

NCT04050709 PHASE1 COMPLETED

Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with locally advanced or metastatic solid cancers.

Details

Lead sponsor	ImmunityBio, Inc.
Phase	PHASE1
Status	COMPLETED
Enrolment	16
Start date	Thu Jul 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Mar 25 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Locally Advanced Solid Tumor
• Metastatic Cancer
• Solid Tumor

Interventions

• PD-L1 t-haNK

Countries

United States